Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254332 · ClinicalTrials.gov registry record
Effect of Denileukin Diftitox on Immune System in CTCL Patients
A clinical trial of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00254332: Completed study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by University of Pittsburgh.
NCT00254332 is a study of Cutaneous T Cell Lymphoma and Mycosis Fungoides that has completed, run by University of Pittsburgh. The registered enrollment target is 10 participants, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00254332, a study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. Blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsubrgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-09 |
What the finished NCT00254332 record still lists
NCT00254332 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT00254332 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00254332 about?
NCT00254332 is a clinical study titled "Effect of Denileukin Diftitox on Immune System in CTCL Patients". This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to pa...
What is the current status of trial NCT00254332?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2005-11. Estimated completion is 2007-09.
What conditions does trial NCT00254332 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome.
Who is sponsoring clinical trial NCT00254332?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00254332 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00254332's enrollment target sits among peer trials
10 23rd of 23 the lowest of 23 other Cutaneous T Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous T Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
RECRUITING
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia